Paul M. K. Gordon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Paul M. K. Gordon has a total of 676 co-authors. Here are the top co-authors by number of shared publications:
- Christoph Wilhelm Sensen
Institute of Computational Biotechnology, Graz University of Technology, Graz, Austria
19 shared publications - Akira R. Kinjo
Department of Mathematics, Faculty of Science, Universiti Brunei Darussalam, Gadong, Brunei Darussalam
3 shared publications - Atsuko Yamaguchi
Tokyo City University, Setagaya, Tokyo, Japan
3 shared publications - Emma J. Griffiths
Centre for Infectious Disease Genomics and One Health, Faculty of Health Sciences, Simon Fraser University
3 shared publications - Fiona S. L. Brinkman
Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
3 shared publications - Gary Van Domselaar
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
3 shared publications
Latest Publications
- 1 July 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (8) , 1-19
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors
Chimeric antigen receptor (CAR) T cell therapy for solid tumors is constrained by the scarcity of safe, uniformly expressed cell-surface targets. Here we identify glycoprotein NMB (GPNMB)—an MiT/TFE-family fusion-driven protein—as being highly, homogeneously and stably expressed in primary and relapsed alveolar soft-part sarcoma (ASPS) and translocation renal cell carcinoma. We develop a GPNMB-directed CAR T cell product, GCAR1, which demonstrates potent activity against patient-matched cells, organoids and xenograft models. Post hoc interim analysis of a first-in-human open-label, individual-participant trial (NCT07104682) for a participant with relapsed/refractory, metastatic ASPS showed that GCAR1 induces stable disease for up to 3 months, accompanied by resolution of many nontarget lesions (primary endpoint), and is well tolerated. GCAR1 T cells expand in peripheral blood as a polyclonal population and remain detectable for 1 month. Spatial transcriptomics identified immunosuppressive niches in a treatment-resistant lesion and immune checkpoint blockade synergized with GCAR1 in a xenograft model. Altogether, our data provide a proof of concept for treating GPNMB-expressing solid tumors with GCAR1 and more broadly targeting surface antigens driven by oncogenic gene fusions with CAR T cell therapies.
- 1 July 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (8) , 1-19
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors
Chimeric antigen receptor (CAR) T cell therapy for solid tumors is constrained by the scarcity of safe, uniformly expressed cell-surface targets. Here we identify glycoprotein NMB (GPNMB)—an MiT/TFE-family fusion-driven protein—as being highly, homogeneously and stably expressed in primary and relapsed alveolar soft-part sarcoma (ASPS) and translocation renal cell carcinoma. We develop a GPNMB-directed CAR T cell product, GCAR1, which demonstrates potent activity against patient-matched cells, organoids and xenograft models. Post hoc interim analysis of a first-in-human open-label, individual-participant trial (NCT07104682) for a participant with relapsed/refractory, metastatic ASPS showed that GCAR1 induces stable disease for up to 3 months, accompanied by resolution of many nontarget lesions (primary endpoint), and is well tolerated. GCAR1 T cells expand in peripheral blood as a polyclonal population and remain detectable for 1 month. Spatial transcriptomics identified immunosuppressive niches in a treatment-resistant lesion and immune checkpoint blockade synergized with GCAR1 in a xenograft model. Altogether, our data provide a proof of concept for treating GPNMB-expressing solid tumors with GCAR1 and more broadly targeting surface antigens driven by oncogenic gene fusions with CAR T cell therapies.
- Open Access
- 7 October 2025
- Published by Oxford University Press (OUP) in NAR Genomics and Bioinformatics
- Vol. 7 (4)
VIRUS-MVP: a framework for comprehensive surveillance of viral mutations and their functional impacts
As viruses evolve, they accumulate genetic mutations that can influence disease severity, transmissibility, and the effectiveness of vaccines and therapeutics. Real-time tracking of viral mutations and their functional impacts is essential to understand these changes and assess their implications for public health responses. VIRUS-MVP is an interactive, portable platform designed for the comprehensive surveillance of viral mutations. Initially developed for SARS-CoV-2, it now fully supports mpox and is expanding to include influenza and RSV. The platform links viral mutations to functional annotations, providing insights into their predicted effects on viral infectivity, immune evasion, and protein functionality. It features an interactive interface for visualizing mutation distributions, a modular and reproducible genomics workflow, and a curated annotation resource that captures known impacts on viral proteins and host interactions. Users can also import custom functional annotations to tailor analyses to specific research needs or emerging pathogens. Developed collaboratively with public health and academic partners, VIRUS-MVP enhances understanding of viral evolution and its public health impact by bridging genomic data with biological insights. The platform is open-source, adaptable, and accessible on GitHub.
- 7 October 2025
- Published by Oxford University Press (OUP) in NAR Genomics and Bioinformatics
- Vol. 7 (4)
Open AccessVIRUS-MVP: a framework for comprehensive surveillance of viral mutations and their functional impacts
As viruses evolve, they accumulate genetic mutations that can influence disease severity, transmissibility, and the effectiveness of vaccines and therapeutics. Real-time tracking of viral mutations and their functional impacts is essential to understand these changes and assess their implications for public health responses. VIRUS-MVP is an interactive, portable platform designed for the comprehensive surveillance of viral mutations. Initially developed for SARS-CoV-2, it now fully supports mpox and is expanding to include influenza and RSV. The platform links viral mutations to functional annotations, providing insights into their predicted effects on viral infectivity, immune evasion, and protein functionality. It features an interactive interface for visualizing mutation distributions, a modular and reproducible genomics workflow, and a curated annotation resource that captures known impacts on viral proteins and host interactions. Users can also import custom functional annotations to tailor analyses to specific research needs or emerging pathogens. Developed collaboratively with public health and academic partners, VIRUS-MVP enhances understanding of viral evolution and its public health impact by bridging genomic data with biological insights. The platform is open-source, adaptable, and accessible on GitHub.
- Open Access
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Apollo: a comprehensive GPU-powered within-host simulator for viral evolution and infection dynamics across population, tissue, and cell
Modern sequencing instruments bring unprecedented opportunity to study within-host viral evolution in conjunction with viral transmissions between hosts. However, no computational simulators are available to assist the characterization of within-host dynamics. This limits our ability to interpret epidemiological predictions incorporating within-host evolution and to validate computational inference tools. To fill this need we developed Apollo, a GPU-accelerated, out-of-core tool for within-host simulation of viral evolution and infection dynamics across population, tissue, and cellular levels. Apollo is scalable to hundreds of millions of viral genomes and can handle complex demographic and population genetic models. Apollo can replicate real within-host viral evolution; accurately recapturing observed viral sequences from HIV and SARS-CoV-2 cohorts derived from initial population-genetic configurations. For practical applications, using Apollo-simulated viral genomes and transmission networks, we validated and uncovered the limitations of a widely used viral transmission inference tool.
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessApollo: a comprehensive GPU-powered within-host simulator for viral evolution and infection dynamics across population, tissue, and cell
Modern sequencing instruments bring unprecedented opportunity to study within-host viral evolution in conjunction with viral transmissions between hosts. However, no computational simulators are available to assist the characterization of within-host dynamics. This limits our ability to interpret epidemiological predictions incorporating within-host evolution and to validate computational inference tools. To fill this need we developed Apollo, a GPU-accelerated, out-of-core tool for within-host simulation of viral evolution and infection dynamics across population, tissue, and cellular levels. Apollo is scalable to hundreds of millions of viral genomes and can handle complex demographic and population genetic models. Apollo can replicate real within-host viral evolution; accurately recapturing observed viral sequences from HIV and SARS-CoV-2 cohorts derived from initial population-genetic configurations. For practical applications, using Apollo-simulated viral genomes and transmission networks, we validated and uncovered the limitations of a widely used viral transmission inference tool.
- Open Access
VIRUS-MVP: A framework for comprehensive surveillance of viral mutations and their functional impacts
As viruses evolve, they accumulate genetic mutations that can influence disease severity, transmissibility, and the effectiveness of vaccines and therapeutics. Real-time tracking of viral mutations and their functional impacts is essential to understand these changes and assess their implications for public health responses. VIRUS-MVP is an interactive, portable platform designed for the comprehensive surveillance of viral mutations. Initially developed for SARS-CoV-2, it now fully supports mpox and is expanding to include influenza and RSV. The platform links viral mutations to functional annotations, providing insights into their predicted effects on viral infectivity, immune evasion, and protein functionality. It features an interactive interface for visualizing mutation distributions, a modular and reproducible genomics workflow, and a curated annotation resource that captures known impacts on viral proteins and host interactions. Users can also import custom functional annotations to tailor analyses to specific research needs or emerging pathogens. Developed collaboratively with public health and academic partners, VIRUS-MVP enhances understanding of viral evolution and its public health impact by bridging genomic data with biological insights. The platform is open-source, adaptable, and accessible on GitHub.
Open AccessVIRUS-MVP: A framework for comprehensive surveillance of viral mutations and their functional impacts
As viruses evolve, they accumulate genetic mutations that can influence disease severity, transmissibility, and the effectiveness of vaccines and therapeutics. Real-time tracking of viral mutations and their functional impacts is essential to understand these changes and assess their implications for public health responses. VIRUS-MVP is an interactive, portable platform designed for the comprehensive surveillance of viral mutations. Initially developed for SARS-CoV-2, it now fully supports mpox and is expanding to include influenza and RSV. The platform links viral mutations to functional annotations, providing insights into their predicted effects on viral infectivity, immune evasion, and protein functionality. It features an interactive interface for visualizing mutation distributions, a modular and reproducible genomics workflow, and a curated annotation resource that captures known impacts on viral proteins and host interactions. Users can also import custom functional annotations to tailor analyses to specific research needs or emerging pathogens. Developed collaboratively with public health and academic partners, VIRUS-MVP enhances understanding of viral evolution and its public health impact by bridging genomic data with biological insights. The platform is open-source, adaptable, and accessible on GitHub.
- Open Access
- 14 October 2024
- Published by Microbiology Society in Microbial Genomics
- Vol. 10 (10) , 001293
The Canadian VirusSeq Data Portal and Duotang: open resources for SARS-CoV-2 viral sequences and genomic epidemiology
The COVID-19 pandemic led to a large global effort to sequence SARS-CoV-2 genomes from patient samples to track viral evolution and inform the public health response. Millions of SARS-CoV-2 genome sequences have been deposited in global public repositories. The Canadian COVID-19 Genomics Network (CanCOGeN – VirusSeq), a consortium tasked with coordinating expanded sequencing of SARS-CoV-2 genomes across Canada early in the pandemic, created the Canadian VirusSeq Data Portal, with associated data pipelines and procedures, to support these efforts. The goal of VirusSeq was to allow open access to Canadian SARS-CoV-2 genomic sequences and enhanced, standardized contextual data that were unavailable in other repositories and that meet FAIR standards (Findable, Accessible, Interoperable and Reusable). In addition, the portal data submission pipeline contains data quality checking procedures and appropriate acknowledgement of data generators that encourages collaboration. From inception to execution, the portal was developed with a conscientious focus on strong data governance principles and practices. Extensive efforts ensured a commitment to Canadian privacy laws, data security standards, and organizational processes. This portal has been coupled with other resources, such as Viral AI, and was further leveraged by the Coronavirus Variants Rapid Response Network (CoVaRR-Net) to produce a suite of continually updated analytical tools and notebooks. Here we highlight this portal (https://virusseq-dataportal.ca/), including its contextual data not available elsewhere, and the Duotang (https://covarr-net.github.io/duotang/duotang.html), a web platform that presents key genomic epidemiology and modelling analyses on circulating and emerging SARS-CoV-2 variants in Canada. Duotang presents dynamic changes in variant composition of SARS-CoV-2 in Canada and by province, estimates variant growth, and displays complementary interactive visualizations, with a text overview of the current situation. The VirusSeq Data Portal and Duotang resources, alongside additional analyses and resources computed from the portal (COVID-MVP, CoVizu), are all open source and freely available. Together, they provide an updated picture of SARS-CoV-2 evolution to spur scientific discussions, inform public discourse, and support communication with and within public health authorities. They also serve as a framework for other jurisdictions interested in open, collaborative sequence data sharing and analyses.
- 14 October 2024
- Published by Microbiology Society in Microbial Genomics
- Vol. 10 (10) , 001293
Open AccessThe Canadian VirusSeq Data Portal and Duotang: open resources for SARS-CoV-2 viral sequences and genomic epidemiology
The COVID-19 pandemic led to a large global effort to sequence SARS-CoV-2 genomes from patient samples to track viral evolution and inform the public health response. Millions of SARS-CoV-2 genome sequences have been deposited in global public repositories. The Canadian COVID-19 Genomics Network (CanCOGeN – VirusSeq), a consortium tasked with coordinating expanded sequencing of SARS-CoV-2 genomes across Canada early in the pandemic, created the Canadian VirusSeq Data Portal, with associated data pipelines and procedures, to support these efforts. The goal of VirusSeq was to allow open access to Canadian SARS-CoV-2 genomic sequences and enhanced, standardized contextual data that were unavailable in other repositories and that meet FAIR standards (Findable, Accessible, Interoperable and Reusable). In addition, the portal data submission pipeline contains data quality checking procedures and appropriate acknowledgement of data generators that encourages collaboration. From inception to execution, the portal was developed with a conscientious focus on strong data governance principles and practices. Extensive efforts ensured a commitment to Canadian privacy laws, data security standards, and organizational processes. This portal has been coupled with other resources, such as Viral AI, and was further leveraged by the Coronavirus Variants Rapid Response Network (CoVaRR-Net) to produce a suite of continually updated analytical tools and notebooks. Here we highlight this portal (https://virusseq-dataportal.ca/), including its contextual data not available elsewhere, and the Duotang (https://covarr-net.github.io/duotang/duotang.html), a web platform that presents key genomic epidemiology and modelling analyses on circulating and emerging SARS-CoV-2 variants in Canada. Duotang presents dynamic changes in variant composition of SARS-CoV-2 in Canada and by province, estimates variant growth, and displays complementary interactive visualizations, with a text overview of the current situation. The VirusSeq Data Portal and Duotang resources, alongside additional analyses and resources computed from the portal (COVID-MVP, CoVizu), are all open source and freely available. Together, they provide an updated picture of SARS-CoV-2 evolution to spur scientific discussions, inform public discourse, and support communication with and within public health authorities. They also serve as a framework for other jurisdictions interested in open, collaborative sequence data sharing and analyses.
- 8 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6662) , 1066-+
Kupffer cell–like syncytia replenish resident macrophage function in the fibrotic liver
Kupffer cells (KCs) are localized in liver sinusoids but extend pseudopods to parenchymal cells to maintain their identity and serve as the body’s central bacterial filter. Liver cirrhosis drastically alters vascular architecture, but how KCs adapt is unclear. We used a mouse model of liver fibrosis and human tissue to examine immune adaptation. Fibrosis forced KCs to lose contact with parenchymal cells, down-regulating “KC identity,” which rendered them incapable of clearing bacteria. Commensals stimulated the recruitment of monocytes through CD44 to a spatially distinct vascular compartment. There, recruited monocytes formed large aggregates of multinucleated cells (syncytia) that expressed phenotypical KC markers and displayed enhanced bacterial capture ability. Syncytia formed via CD36 and were observed in human cirrhosis as a possible antimicrobial defense that evolved with fibrosis.
- 8 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6662) , 1066-+
Kupffer cell–like syncytia replenish resident macrophage function in the fibrotic liver
Kupffer cells (KCs) are localized in liver sinusoids but extend pseudopods to parenchymal cells to maintain their identity and serve as the body’s central bacterial filter. Liver cirrhosis drastically alters vascular architecture, but how KCs adapt is unclear. We used a mouse model of liver fibrosis and human tissue to examine immune adaptation. Fibrosis forced KCs to lose contact with parenchymal cells, down-regulating “KC identity,” which rendered them incapable of clearing bacteria. Commensals stimulated the recruitment of monocytes through CD44 to a spatially distinct vascular compartment. There, recruited monocytes formed large aggregates of multinucleated cells (syncytia) that expressed phenotypical KC markers and displayed enhanced bacterial capture ability. Syncytia formed via CD36 and were observed in human cirrhosis as a possible antimicrobial defense that evolved with fibrosis.
- 28 July 2022
- Published by Elsevier in American Journal of Infection Control
- Vol. 50 (8) , 906-908
Methylene blue in combination with sunlight as a low cost and effective disinfection method for coronavirus-contaminated PPE
- 28 July 2022
- Published by Elsevier in American Journal of Infection Control
- Vol. 50 (8) , 906-908
Methylene blue in combination with sunlight as a low cost and effective disinfection method for coronavirus-contaminated PPE
- Open Access
- 15 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0261422
Reconstructing SARS-CoV-2 infection dynamics through the phylogenetic inference of unsampled sources of infection
The COVID-19 pandemic has illustrated the importance of infection tracking. The role of asymptomatic, undiagnosed individuals in driving infections within this pandemic has become increasingly evident. Modern phylogenetic tools that take into account asymptomatic or undiagnosed individuals can help guide public health responses. We finetuned established phylogenetic pipelines using published SARS-CoV-2 genomic data to examine reasonable estimate transmission networks with the inference of unsampled infection sources. The system utilised Bayesian phylogenetics and TransPhylo to capture the evolutionary and infection dynamics of SARS-CoV-2. Our analyses gave insight into the transmissions within a population including unsampled sources of infection and the results aligned with epidemiological observations. We were able to observe the effects of preventive measures in Canada’s “Atlantic bubble” and in populations such as New York State. The tools also inferred the cross-species disease transmission of SARS-CoV-2 transmission from humans to lions and tigers in New York City’s Bronx Zoo. These phylogenetic tools offer a powerful approach in response to both the COVID-19 and other emerging infectious disease outbreaks.
- 15 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0261422
Open AccessReconstructing SARS-CoV-2 infection dynamics through the phylogenetic inference of unsampled sources of infection
The COVID-19 pandemic has illustrated the importance of infection tracking. The role of asymptomatic, undiagnosed individuals in driving infections within this pandemic has become increasingly evident. Modern phylogenetic tools that take into account asymptomatic or undiagnosed individuals can help guide public health responses. We finetuned established phylogenetic pipelines using published SARS-CoV-2 genomic data to examine reasonable estimate transmission networks with the inference of unsampled infection sources. The system utilised Bayesian phylogenetics and TransPhylo to capture the evolutionary and infection dynamics of SARS-CoV-2. Our analyses gave insight into the transmissions within a population including unsampled sources of infection and the results aligned with epidemiological observations. We were able to observe the effects of preventive measures in Canada’s “Atlantic bubble” and in populations such as New York State. The tools also inferred the cross-species disease transmission of SARS-CoV-2 transmission from humans to lions and tigers in New York City’s Bronx Zoo. These phylogenetic tools offer a powerful approach in response to both the COVID-19 and other emerging infectious disease outbreaks.
- Open Access
- 10 September 2021
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 17 (9) , e1009350
Evaluating the effectiveness of ensemble voting in improving the accuracy of consensus signals produced by various DTWA algorithms from step-current signals generated during nanopore sequencing
Nanopore sequencing device analysis systems simultaneously generate multiple picoamperage current signals representing the passage of DNA or RNA nucleotides ratcheted through a biomolecule nanopore array by motor proteins. Squiggles are a noisy and time-distorted representation of an underlying nucleotide sequence, “gold standard model”, due to experimental and algorithmic artefacts. Other research fields use dynamic time warped-space averaging(DTWA)algorithms to produce a consensus signal from multiple time-warped sources while preserving key features distorted by standard, linear-averaging approaches. We compared the ability ofDTWBarycentre averaging (DBA), minimize mean (MM) and stochastic sub-gradient descent (SSG) DTWAalgorithms to generate a consensus signal from squiggle-space ensembles of RNA moleculesEnolase,Sequin R1-71-1andSequin R2-55-3without knowledge of their associated gold standard model. We propose techniques to identify the leader and distorted squiggle features prior toDTWAconsensus generation. New visualization and warping-path metrics are introduced to compare consensus signals and the best estimate of the “true” consensus, the study’s gold standard model. TheDBAconsensus was the best match to the gold standard for bothSequinstudies but was outperformed in theEnolasestudy. Given an underlying common characteristic across a squiggle ensemble, we objectively evaluate a novel “voting scheme” that improves the local similarity between the consensus signal and a given fraction of the squiggle ensemble. While the gold standard is not used during voting, the increase in the match of the final voted-on consensus to the underlyingEnolaseandSequingold standard sequences provides an indirect success measure for the proposed voting procedure in two ways: First is the decreased least squares warped distance between the final consensus and the gold model, and second, the voting generates a final consensus length closer to the known underlying RNA biomolecule length. The results suggest considerable potential in marrying squiggle analysis andvoted-on DTWAconsensus signals to provide low-noise, low-distortion signals. This will lead to improved accuracy in detecting nucleotides and their deviation model due to chemical modifications (a.k.a. epigenetic information). The proposed combination of ensemble voting andDTWAhas application in other research fields involving time-distorted, high entropy signals.
- 10 September 2021
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 17 (9) , e1009350
Open AccessEvaluating the effectiveness of ensemble voting in improving the accuracy of consensus signals produced by various DTWA algorithms from step-current signals generated during nanopore sequencing
Nanopore sequencing device analysis systems simultaneously generate multiple picoamperage current signals representing the passage of DNA or RNA nucleotides ratcheted through a biomolecule nanopore array by motor proteins. Squiggles are a noisy and time-distorted representation of an underlying nucleotide sequence, “gold standard model”, due to experimental and algorithmic artefacts. Other research fields use dynamic time warped-space averaging(DTWA)algorithms to produce a consensus signal from multiple time-warped sources while preserving key features distorted by standard, linear-averaging approaches. We compared the ability ofDTWBarycentre averaging (DBA), minimize mean (MM) and stochastic sub-gradient descent (SSG) DTWAalgorithms to generate a consensus signal from squiggle-space ensembles of RNA moleculesEnolase,Sequin R1-71-1andSequin R2-55-3without knowledge of their associated gold standard model. We propose techniques to identify the leader and distorted squiggle features prior toDTWAconsensus generation. New visualization and warping-path metrics are introduced to compare consensus signals and the best estimate of the “true” consensus, the study’s gold standard model. TheDBAconsensus was the best match to the gold standard for bothSequinstudies but was outperformed in theEnolasestudy. Given an underlying common characteristic across a squiggle ensemble, we objectively evaluate a novel “voting scheme” that improves the local similarity between the consensus signal and a given fraction of the squiggle ensemble. While the gold standard is not used during voting, the increase in the match of the final voted-on consensus to the underlyingEnolaseandSequingold standard sequences provides an indirect success measure for the proposed voting procedure in two ways: First is the decreased least squares warped distance between the final consensus and the gold model, and second, the voting generates a final consensus length closer to the known underlying RNA biomolecule length. The results suggest considerable potential in marrying squiggle analysis andvoted-on DTWAconsensus signals to provide low-noise, low-distortion signals. This will lead to improved accuracy in detecting nucleotides and their deviation model due to chemical modifications (a.k.a. epigenetic information). The proposed combination of ensemble voting andDTWAhas application in other research fields involving time-distorted, high entropy signals.
- 23 January 2021
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 22 (5)
Oxford nanopore sequencing in clinical microbiology and infection diagnostics
Extended turnaround times and large economic costs hinder the usage of currently applied screening methods for bacterial pathogen identification (ID) and antimicrobial susceptibility testing. This review provides an overview of current detection methods and their usage in a clinical setting. Issues of timeliness and cost could soon be circumvented, however, with the emergence of detection methods involving single molecule sequencing technology. In the context of bringing diagnostics closer to the point of care, we examine the current state of Oxford Nanopore Technologies (ONT) products and their interaction with third-party software/databases to assess their capabilities for ID and antimicrobial resistance (AMR) prediction. We outline and discuss a potential diagnostic workflow, enumerating (1) rapid sample prep kits, (2) ONT hardware/software and (3) third-party software and databases to improve the cost, accuracy and turnaround times for ID and AMR. Multiple studies across a range of infection types support that the speed and accuracy of ONT sequencing is now such that established ID and AMR prediction tools can be used on its outputs, and so it can be harnessed for near real time, close to the point-of-care diagnostics in common clinical circumstances.
- 23 January 2021
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 22 (5)
Oxford nanopore sequencing in clinical microbiology and infection diagnostics
Extended turnaround times and large economic costs hinder the usage of currently applied screening methods for bacterial pathogen identification (ID) and antimicrobial susceptibility testing. This review provides an overview of current detection methods and their usage in a clinical setting. Issues of timeliness and cost could soon be circumvented, however, with the emergence of detection methods involving single molecule sequencing technology. In the context of bringing diagnostics closer to the point of care, we examine the current state of Oxford Nanopore Technologies (ONT) products and their interaction with third-party software/databases to assess their capabilities for ID and antimicrobial resistance (AMR) prediction. We outline and discuss a potential diagnostic workflow, enumerating (1) rapid sample prep kits, (2) ONT hardware/software and (3) third-party software and databases to improve the cost, accuracy and turnaround times for ID and AMR. Multiple studies across a range of infection types support that the speed and accuracy of ONT sequencing is now such that established ID and AMR prediction tools can be used on its outputs, and so it can be harnessed for near real time, close to the point-of-care diagnostics in common clinical circumstances.